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ABSTRACT
Interleukin (IL)-13 is a Th-2 cytokine, known to be involved in allergic diseases. Although IL-13 and another Th-
2 cytokine, IL-4, share receptors and signal pathways, having similar biological properties, the critical role of IL-
13 alone in vivo in the pathogenesis of bronchial asthma has recently been recognized, based mainly on analy-
ses of mouse models. IL-13 and its signal pathway are thought to be promising targets to develop a therapeutic
agent for bronchial asthma. In this article, we summarize the signal transduction pathway of IL-13, the patho-
logical roles of IL-13 in bronchial asthma, and possible therapeutic strategies to block the IL-13 signal．
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INTRODUCTION
Bronchial asthma is a complex disease caused by a
combination of multiple genetic and environmental
factors.1,2 Improved hygiene, resulting in a decrease
in childhood infections, has been thought to be an im-
portant environmental factor . 3,4 This would explain
why the prevalence of allergic diseases , including
bronchial asthma, has dramatically increased in de-
veloped areas in the last few decades. By contrast, ge-
netic factors must have been unchanged in such a
relatively short period . Although hundreds of re-
searchers have listed several potential genetic factors
that may affect disease susceptibility, there has been
no successful attempt to target any specific genetic
factors to treat bronchial asthma.5,6 Nevertheless, a
growing body of genetic and clinical evidence that
these cytokines are critical in the pathophysiology of
asthma both in mouse and human, raises the possibil-
ity that inhibition of T helper (Th)-2 cytokines such
as interleukin (IL)-4, IL-5, and IL-13 could be a logical
approach to asthma therapy.6,7 Of these, we summa-
rize here the pathophysiological roles of IL-13 in
bronchial asthma and the therapeutic strategies to in-
hibit its signaling pathway．
IL-13 RECEPTOR SYSTEM
IL-13 is a pleiotropic cytokine, playing key roles in
the pathogenesis of allergic diseases such as bron-
chial asthma and atopic dermatitis, and in the host de-
fense processes against parasite infection.7-9 It exerts
its many actions through interaction with specific re-
ceptors expressed on the surface of target cells (Fig.
1 ) . IL-13 binds to a low-affinity IL-13 receptor α1
chain (IL-13Rα1) 10,11 or to a high-affinity IL-13 recep-
tor α2 chain (IL-13Rα2).12,13 IL-13IL-13Rα1 complex
recruits the second receptor subunit, IL-4 receptor α
chain ( IL-4Rα ) , which is also the high-affinity α-
receptor subunit for IL-4. This oligomerization acti-
vates the Janus kinases (JAKs) to phosphorylate tyro-
sine residues of the signaling molecules , including
the signal transducer and activator of transcription
(STAT) proteins. Phosphorylated STAT-6 in turn mi-
grates to the nucleus and activates transcription of
genes encoding germline ε transcript , CD23, and
MHC class II in B cells, IL-4 and IL-13 in T cells, CCL
11 (eotaxin) in fibroblasts, and a chloride channel hu-
man CLCA1 (mouse CLCA3) in bronchial epithelial
cells . 8 As either IL-13 or IL-4 activates STAT-6
through a shared receptor chain, IL-4Rα,they share
most biological activities.7,14-16 IL-13Rα2 binds IL-13
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Fig. 1 The receptor structure and signal transduction me-
chanism of IL-13. IL-13 binds to IL-13 receptor (IL-13R), 
which is composed of IL-4Rα and IL-13Rα1. IL-13R also 
acts as IL-4R. Engagement of the receptor causes signal 
transduction, mainly through the JAK-STAT pathway. IL-13 
also binds to IL-13Rα2, although this receptor does not tra-
nsduce the signal, acting as a decoy receptor. 
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with even higher affinity than IL-13Rα1 but appears
to be a non-signaling “decoy” receptor, because it is
not known to oligomerize with any cytokine receptor
subunit upon binding of IL-13 and its cytoplasmic tail
is too short to transduce intracellular signals . 13,17
When IL-13Rα2 is expressed on some cell lines ,
STAT-6 activation by IL-13 via IL-13Rα1‐containing
receptor complex is blocked, because IL-13 is com-
petitively bound by IL-13Rα2.17-19
The biological activities of IL-4 and IL-13 are very
similar because of their shared receptor system .
However, knocking out the IL13 gene but not the IL4
gene in mice prevents the development of asthmatic
phenotypes upon allergen challenge.20 Thus, the in
vivo function of IL-13 seems to be different from that
of IL-4, whicn can signal without IL-13Rα1 in most im-
mune cells with the help of the IL-2 receptor γ chain.
In T cells, which lack IL-13Rα1, IL-13 transduces very
little amount of signal ; in resting B cells, which ex-
press the receptor at a very low level, IL-13 is simi-
larly weak.14,21 In contrast, IL-13Rα1 is abundantly ex-
pressed in many non-hematopoietic tissues, including
lung.22,23 Although it is uncertain whether an IL-13-
specific signal is present in such tissues, the predomi-
nant activity of IL-13 may be deduced by the different
spatial and temporal patterns of expression of IL-4, IL-
13, and their receptor subunits in the tissue. Conse-
quently, the biological activities of IL-4 and IL-13 in
vivo are skewed towards immune cells and non-
immune tissues, respectively.7
SIGNIFICANCE OF IL-13 IN THE PATHO-
GENESIS OF BRONCHIAL ASTHMA
Bronchial asthma is caused by various genetic and
environmental factors,1 which result in infiltration of
Th-2 lymphocytes , mast cells , and eosinophils into
the bronchial lesions with downstream inflammatory
mediators released, impairing the airway function.7,8
Cytokines derived from the Th-2 lymphocytes are
considered to orchestrate the asthmatic phenotype.
Among the Th-2 cytokines, substantial evidence sup-
ports key roles for IL-4 and IL-13 in the pathogenesis
of bronchial asthma. Such evidence is classified into
the following categories．
ANALYSES OF MOUSE MODELS
Analyses of knock-out mice for any components of
the IL-4 and IL-13 signal transduction system includ-
ing IL-4, IL-13, IL-4Rα and STAT-6 have revealed that
both cytokines play a pivotal role in induction of air-
way hyperresponsiveness ( AHR ) . Furthermore ,
either epithelial overexpression of an IL13 transgene
or administration of IL-13 to mice has shown that IL-
13 alone can induce many of the features of asthma,
including AHR, mucus hypersecretion, and airway fi-
brosis.24-26 It has been further revealed that the target
cells of IL-13 in such situations are mainly bronchial
epithelial cells.27
EXPRESSION OF IL-4 AND IL-13 IN THE BRON-
CHIAL LESIONS
Augmented expression of IL-4 and IL-13 in bronchial
tissues or bronchoalveolar lavage fluids derived from
asthma patients is observed at the baseline and after
allergen challenge . Particularly , IL-13 is predomi-
nantly expressed, compared to IL-4.28,29
GENETIC ASSOCIATION OF THE IL-4 AND IL-13
SIGNALING MOLECULES
Genetic predisposition to allergic diseases is thought
to be polygenic, and the genetic factors are thought
to exist among genetic polymorphisms.30 Extensive
efforts have been made to identify such factors by
genome-wide scanning and by candidate-gene stud-
ies. Based on the latter, it has been reported that sev-
eral genetic polymorphisms of genes encoding IL-4
and IL-13 signaling molecules such as IL 4, IL 13,
IL2RG, IL4RA, IL13RA1, STAT6, and BCL6 are ge-
netically associated with asthma or atopic status . 31
Among the single nucleotide polymorphisms (SNPs)
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that are demonstrated to be associated with bronchial
asthma or atopy , we have analyzed the functional
properties of variants of IL4RA (Ile50Val) and IL13
(Gln110Arg). The variant of IL-4Rα whose amino acid
at 50 is isoleucine upregulates response to IL-4, lead-
ing to increased activation of STAT-6 and IgE synthe-
sis, compared to the valine type.32,33 The variant of IL-
13 whose amino acid at 110 is glutamine has less af-
finity with IL-13Rα2, a decoy receptor , and an en-
hanced stability, compared to the arginine type, caus-
ing upregulation of the IL-13 concentration in
vivo.22,34 These results clearly show that genetic vari-
ation is not only a disease-susceptibility marker but
also a causative factor for a biologically functional dif-
ference．
TARGETING IL-13 TO DEVELOP A NEW
AGENT FOR ALLERGIC DISEASES
In general, there are several possible approaches to
targeting specific cytokines. These include drugs that
inhibit cytokine production such as glucocorticoids
and tacrolimus, blocking antibodies to cytokines or
their receptors ; soluble receptors to adsorb secreted
cytokines ; and low molecular weight compounds that
potentially block the signal transduction pathways ac-
tivated by cytokine receptors.
Because Th-2 cytokines have a critical role in the
pathogenesis of allergic diseases, particularly of bron-
chial asthma, it is reasonable that blocking their bio-
logical activities should be an ideal strategy to treat
bronchial asthma.6,7,35 The potential target is either
IL-4 or IL-5 or IL-13. However, anti―IL-4 and anti―IL-5
therapies have been withdrawn because of their insig-
nificant effect for treating AHR.35,36 Clinical trials of
humanized anti―IL-5 antibody to asthma showed that
this antibody was not effective for AHR, although it
was effective for reduction of eosinophilia in blood
and, to a lesser extent, in lung tissues, inhibiting air-
way remodeling.36,37 A single nebulized dose of sol-
uble IL-4Rα (sIL-4Rα) prevents the decrease in lung
function induced by withdrawal of inhaled corticoster-
oids in patients with moderately severe asthma,38 and
weekly nebulization of sIL-4Rα improved asthma con-
trol over a 12-week period.39 However , subsequent
studies in patients with milder asthma proved that it
was not significantly effective.35
These facts, together with a substantial body of evi-
dence that IL-13 is a central mediator in the patho-
genesis of bronchial asthma, prompted us to explore
whether the blockage of IL-13 could work for dimin-
ishing the asthmatic phenotypes, including AHR. Be-
cause we focused on the IL-13IL-13 receptor interac-
tion as a therapeutic target in this article, potential IL-
13 inhibitors at the receptor level are listed below
(Table 1)．
SOLUBLE IL-13R
Blocking actions of cytokines by administration of
their soluble receptors is now widely accepted as a
promising strategy for treating various diseases. For
example, soluble TNF receptor (EnbrelⓇ ) has been
shown to be effective for rheumatoid arthritis.40 As
mentioned earlier , it has been shown that IL-13 is
more important than IL-4 in inducing asthmatic phe-
notypes in the mouse, and that sIL-4Rα that blocks
IL-4 but not IL-13 was so ineffective that further devel-
opment of sIL-4Rα as a potential therapeutic modality
was terminated. Based on such results, a recombi-
nant soluble IL-13R (sIL-13R) has also been consid-
ered for asthma treatment. Two candidates of sIL-13R
exist : sIL-13Rα1 and sIL-13Rα2. Because the affinity
of IL-13Rα2 with IL-13 (Kd ; 50―500 pM) is more
than 10-fold higher than that of IL-13Rα1 (Kd ; -4
nM), sIL-13Rα2 has superior potency as a blocking
agent.10,11,34 In a mouse model , an inhaled admini-
stration of sIL-13Rα2-Fc protein was reported to be ef-
fective for suppressing AHR and eosinophilia.25,26 For
human asthma, a recombinant protein denoted IL-4
13 Trap, in which sIL-13Rα1 and sIL-4Rα are tandem
lined , 41 was developed , and is being evaluated in
Phase I clinical testing. Further trials conducted with
asthma patients are awaited.
IL-4 MUTEIN
Some bioengineered versions (muteins) of IL-4 have
been developed. These include variants whose tyro-
sine at 124 is replaced with aspartate (Y124D), and ar-
ginine at 121 is additionally replaced with aspartate
(R121DY124D). The R121DY124D mutein acts as
an IL-4IL-13 antagonist because it is able to bind to
the shared receptor subunit, IL-4Rα, but not able to
transduce the signal.42,43 Multi-center Phase I clinical
safety trials of this molecule to asthma have already
started . A recent study with a mouse model has
shown that, although a mouse version of IL-4 mutein
can efficiently prevent the development of the asth-
matic phenotype when applied during allergen chal-
lenge , it is ineffective when applied after allergen
challenge.44 Because an IL-13―specific inhibitor, sIL-
13Rα2-Fc, can prevent asthma development in mice
when applied even after allergen challenge , 25 this
means that IL-13 could act without IL-4Rα to modu-
late pathogenesis.45
OTHER IL-13 ANTAGONISTS
In mouse models, immunoneutralization of IL-13 but
not IL-4 has been shown to be effective in fungus-
induced asthma and in respiratory syncytial virus-
induced AHR.46,47 However, anti―IL-13 antibody has
never been applied to human asthma treatment．
A STRATEGY FOR APPLYING THE FIND-
INGS ABOUT THE IL-13 VARIANT TO THE
DEVELOPMENT OF A NEW AGENT
As described earlier , the affinity of IL-13 with
IL-13Rα2 is much higher than IL-13Rα1. Analyses of
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Table 1 List of IL-13 Antagonist
ReferencesIL-13 blockIL-4 blockAgent
25, 26＋－Soluble IL-13Rα2-Fc
41＋＋IL-4/13 Trap (IL-13Rα1/IL-4Rα chimera)
42, 43, 44＋＋IL-4 mutein (R121D/Y124D)
46, 47＋?Anti-IL-13Rα1 Antibody
the IL-13 variant have demonstrated that the variant
which bears glutamine at amino acid 110 (Gln110)
has a lower affinity with IL-13Rα2 than the arginine
type (Arg110), whereas both IL-13 proteins show the
same affinity with IL-13R.34 To explain these binding
properties with respect to molecular structure , we
have constructed a homology model of the complex
(Arima K . , unpublished data ) . According to this
model , it is initially predicted that there exist five
ionic interactions between amino acid residues of IL-
13 and IL-13Rα2. In contrast, only three ionic interac-
tions are predicted between IL-13 and IL-13Rα1. The
loss of two ionic interactions could explain why the af-
finity of IL-13 with IL-13Rα1 is lower than IL-13Rα2.
In this context, the IL-13 variant (Gln110) is as-
sumed to lose one ionic bond compared with Arg110,
weakening the affinity with IL-13Rα2, whereas it does
not affect the affinity with IL-13Rα1．
We are now attempting to validate this model by in-
corporating mutations into the ligandreceptor inter-
face, including predicted ionic interaction residues.
We have found that some interactions other than
ionic bonds are involved in determining the affinity of
IL-13IL-13R interaction (Arima K . , unpublished
data) . If a finely tuned structural model is recon-
structed based on the data from mutagenesis experi-
ments, we may be able to manipulate the affinity be-
tween IL-13 and the IL-13 receptor by incorporating
additional interactive side chains or depleting unfa-
vorable ones. If we could find a mutated type of IL-
13Rα2 that binds IL-13 more firmly, we would be able
to use such a“super receptor”to produce a remod-
eled sIL-13Rα2 that would trap IL-13 more efficiently.
Thus there is a possibility that functional findings
based on the genetic polymorphisms associated with
some diseases might be of great use not only as
disease-susceptibility markers but also for developing
new therapeutic approaches.48
CONCLUSION
In this review article, we described the mechanism of
signal transduction of IL-13, the significance of IL-13
in pathogenesis of bronchial asthma, and the possible
development of novel therapeutic methods for aller-
gic diseases by targeting the IL-13 signal . It is ex-
pected that in the near future , several drugs will
emerge based on these strategies, giving us a wider
choice of treatments, depending on the pathogenesis
of the diseases．
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